ES2061661T3 - Inhibidores de la expresion virica. - Google Patents

Inhibidores de la expresion virica.

Info

Publication number
ES2061661T3
ES2061661T3 ES88307302T ES88307302T ES2061661T3 ES 2061661 T3 ES2061661 T3 ES 2061661T3 ES 88307302 T ES88307302 T ES 88307302T ES 88307302 T ES88307302 T ES 88307302T ES 2061661 T3 ES2061661 T3 ES 2061661T3
Authority
ES
Spain
Prior art keywords
sequence
viric
protein
dna
expression inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307302T
Other languages
English (en)
Inventor
Elliot J Androphy
Douglas R Lowy
John T Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Application granted granted Critical
Publication of ES2061661T3 publication Critical patent/ES2061661T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE TRATA DE METODO DE INHIBICION DEL CRECIMIENTO DE VIRUS CUYO DNA INCLUYA LA SECUENCIA DE ACIDOS NUCLEICOS 5''ACCXNNNPYCGGTXY3'', DONDE X, Y Y N PUEDEN SER CUALQUIER NUCLEOTIDO Y PY ES CO T; LA SECUENCIA ANTES SEÑALADA ES CAPAZ DE LIGARSE A UNA PROTEINA CODIFICADA POR EL DNA DEL VIRUS. ESTA PROTEINA, TRAS UNIRSE A LA SECUENCIA DE NUCLEOTIDOS ES CAPAZ DE INDUCIR UN AUMENTO EN LA TRANSCRIPCION DEL DNA DEL VIRUS. EL METODO SUPONE LA INHIBICION DE LA PROTEINA EN SU UNION A LA SECUENCIA NUCLEOTIDICA PARA REPRIMIR LA TRANSCRIPCION DEL DNA DE DICHO VIRUS, INHIBIENDO ASI SU CRECIMIENTO.
ES88307302T 1987-08-07 1988-08-08 Inhibidores de la expresion virica. Expired - Lifetime ES2061661T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8377187A 1987-08-07 1987-08-07

Publications (1)

Publication Number Publication Date
ES2061661T3 true ES2061661T3 (es) 1994-12-16

Family

ID=22180594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307302T Expired - Lifetime ES2061661T3 (es) 1987-08-07 1988-08-08 Inhibidores de la expresion virica.

Country Status (7)

Country Link
US (1) US5674835A (es)
EP (1) EP0302758B1 (es)
JP (1) JPH01137970A (es)
AT (1) ATE102993T1 (es)
CA (1) CA1339596C (es)
DE (1) DE3888425T2 (es)
ES (1) ES2061661T3 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1991014790A1 (en) * 1990-03-27 1991-10-03 New England Medical Center Hospitals, Inc. Inhibitors of transcription activation activity of papillomaviruses
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
AU671808B2 (en) * 1991-10-11 1996-09-12 Chiron Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998001148A1 (en) 1996-07-09 1998-01-15 President And Fellows Of Harvard College Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7261895B2 (en) * 2001-02-26 2007-08-28 Quattromed Ltd. Peptide tag for monitoring and purification of proteins
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
EP2567972A1 (en) 2011-09-12 2013-03-13 Adriacell S.p.A. Antibodies against E7 protein of Human Papilloma Virus (HPV)
CN107266536A (zh) * 2017-06-27 2017-10-20 广州辉骏生物科技有限公司 一种用于质谱检测的蛋白封闭剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775630A (en) * 1986-08-15 1988-10-04 Vanderbilt University Transcriptional control element adapted for regulation of gene expression in animal cells

Also Published As

Publication number Publication date
EP0302758B1 (en) 1994-03-16
US5674835A (en) 1997-10-07
JPH01137970A (ja) 1989-05-30
CA1339596C (en) 1997-12-23
EP0302758A1 (en) 1989-02-08
DE3888425D1 (de) 1994-04-21
DE3888425T2 (de) 1994-06-23
ATE102993T1 (de) 1994-04-15

Similar Documents

Publication Publication Date Title
ES2061661T3 (es) Inhibidores de la expresion virica.
ATE191513T1 (de) Verfahren zur amplifikation von nukleinsäuren
ATE116857T1 (de) Oligodesoxynukleotide als inhibitoren der replikation von retroviren und der expression von onkogenen.
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DE3885584D1 (de) Verfahren zur Herstellung von austenitischem rostfreien Stahl mit ausgezeichneter Seewasserbeständigkeit.
DE10299011I2 (de) Interleukin-1-Inhibitoren.
DE68915202D1 (de) Verfahren zur Vermehrung und zum Nachweis von Nukleinsäuresequenzen.
DK2230299T3 (da) Hidtil ukendt cytokin ZCYTOR17-ligand
DK1724354T3 (da) Cirkulær DNA-molekyle med en afhængig replikationsoprindelse, fremgangsmåde til fremstilling heraf og anvendelse heraf i genterapi
DE69637726D1 (de) Gruppen zum einfangen von nukleinsäuren
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
DE3886710D1 (de) Verfahren zur selektiven inhibierung von hiv.
DE68926991D1 (de) Verfahren zum Nachweis und zur Identifizierung von Nukleinsäure enthaltenden Teilen
EA199700294A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
DE69936532D1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE152621T1 (de) Behandlungsverfahren kataboler dysfunktion
HUP9901411A2 (hu) Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása
DE3880857D1 (de) Katalysatorzusammensetzungen und verfahren zur copolymerisation von co mit einer oder mehreren ungesaettigten olefinischen verbindungen.
DE68914645D1 (de) Verfahren zur mikrobiologischen reinigung von wasser.
BG97042A (bg) Метод за получаване на растения,резистентни към атаките на sсlеrотiniа sсlеrотiоruм,чрез внасяне на ген,кодиращ оксалатоксидаза
DE3869690D1 (de) Verfahren zur magnetisierung von bohrlochrohren.
DE3689766D1 (de) Monoklonaler antikörper-inhibitor des plasminogenaktivators, hybridomen, herstellung monoklonaler antikörper und deren verwendung zur reinigung, beseitigung, inhibition oder zum testverfahren von inhibitoren.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 302758

Country of ref document: ES